CWM
RLAY icon

Congress Wealth Management’s Relay Therapeutics RLAY Stock Holding History

Congress Wealth Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$644K Hold
186,063
– – 0.01% 840
2025
Q1 		$487K Buy
+186,063
New +$729K 0.01% 823

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Congress Wealth Management's RLAY Position: Q2 2025 in Review

Congress Wealth Management held its Relay Therapeutics (RLAY) position steady in Q2 2025 at 186,063 shares worth $644K. The position accounts for 0.01% of the portfolio, ranked #840.

Congress Wealth Management first reported a position in RLAY in Q1 2025 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold RLAY as of Q2 2025.

  • Congress Wealth Management held 186,063 shares of Relay Therapeutics worth $644K as of Q2 2025.
  • Congress Wealth Management left its Relay Therapeutics share count unchanged in Q2 2025.
  • Relay Therapeutics made up 0.01% of Congress Wealth Management's portfolio in Q2 2025, its #840 holding.
  • Congress Wealth Management first reported a position in Relay Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2025.

Based on Congress Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.